Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegavivint in Pediatric and Young Adult Patients With Recurrent or Refractory Solid Tumors
NCT04851119Phase 2Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Nov 2021
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegavivint in colorectal carcinoma (CRC), endometrial carcinoma, melanoma and 12 more, sponsored by Children's Oncology Group. Primary endpoints: Frequency of dose limiting toxicities at 28 days, Frequency of adverse events at 60 months and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
tegavivint
03
Conditions
colorectal carcinoma (CRC)endometrial carcinomamelanomaneuroblastomaovarian carcinoma
Beyond the preview
Go deeper on NCT04851119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851119.